Treat DVT with low molecular weight heparin.
Each year, deep vein thrombosis (DVT) affects two million Americans, and pulmonary embolism (PE) affects 600,000. Traditional treatment requires hospitalizationto receive continuous intravenous unfractionated heparin (UFH), which has substantial pharmacokinetic limitations. Low molecular weight hepa...
| Publicado en: | Nurse Practitioner Vol. 28; no. 10; pp. 22 - 28 |
|---|---|
| Autores principales: | , |
| Formato: | care plan CEU exam questions Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
Oct2003
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Each year, deep vein thrombosis (DVT) affects two million Americans, and pulmonary embolism (PE) affects 600,000. Traditional treatment requires hospitalizationto receive continuous intravenous unfractionated heparin (UFH), which has substantial pharmacokinetic limitations. Low molecular weight heparins have overcome many of these limitations, resulting in a predictable anticoagulant response without the need for laboratory monitoring or dosage adjustment. |
|---|